Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Hysteroscopy

Hysteroscopy

Hysteroscopy is a minimally invasive diagnostic and therapeutic procedure used to examine the interior of the uterus.
It involves the insertion of a thin, lighted instrument called a hysteroscope through the cervix to visualize the uterine cavity.
Hysteroscopy allows healthcare providers to identify and treat various uterine conditions, such as abnormal bleeding, fibroids, polyps, and adhesions.
This procedure can be performed in an outpatient setting and is generally well-tolerated by patients.
Accurate and reproducible hysteroscopy findings are crucial for effective clinical management.
PubCompare.ai offers an AI-drivne protocol comparrison tool to help reserachers locate, evaluate, and optimize hysteroscopy procedures based on the latest published literature, preprints, and patents.
Experiene the future of hysteroscopy research todya with PubCompare.ai.

Most cited protocols related to «Hysteroscopy»

1
Polycystic Ovary Syndrome Infertility Protocol
A total of 750 infertile women 18 to 40 years of age with the polycystic ovary syndrome who had no major medical disorders and who were not taking confounding medications (primarily sex steroids, other infertility drugs, and insulin sensitizers, as described in the study protocol), their male partners, and their neonates participated in the study.9 (link) We used modified Rotterdam criteria1 to diagnose the polycystic ovary syndrome. Accordingly, all participating women had ovulatory dysfunction combined with hyperandrogenism (on the basis of hirsutism9 (link) or an elevated testosterone level10 (link)), polycystic ovaries (defined by an increased number of small antral follicles [≥12 follicles that were <10 mm in diameter] or an increased individual ovarian volume [>10 cm3] in ≥1 ovary), or both.9 (link) Other disorders that mimic the polycystic ovary syndrome, including thyroid disease and prolactin excess, were ruled out.
Additional eligibility criteria were at least one patent fallopian tube and a normal uterine cavity, as determined by sonohysterography (on the basis of the presence of free fluid in the pelvis), hysterosalpingography, a combined hysteroscopy and laparoscopy, or evidence of an intrauterine pregnancy within the previous 3 years; a male partner with a sperm concentration of at least 14 million per milliliter, with documented motility according to World Health Organization cutoff points,11 (link) in at least one ejaculate during the previous year; and a commitment on the part of the women and their partners to have regular intercourse during the study with the intent of pregnancy.
Legro R.S., Brzyski R.G., Diamond M.P., Coutifaris C., Schlaff W.D., Casson P., Christman G.M., Huang H., Yan Q., Alvero R., Haisenleder D.J., Barnhart K.T., Bates G.W., Usadi R., Lucidi S., Baker V., Trussell J.C., Krawetz S.A., Snyder P., Ohl D., Santoro N., Eisenberg E, & Zhang H. (2014). Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. The New England journal of medicine, 371(2), 119-129.
Publication 2014
Coitus Dental Caries Diagnosis Eligibility Determination Fallopian Tubes Female Infertility Fertility Agents Gonadal Steroid Hormones Graafian Follicle Hair Follicle Hyperandrogenism Hysterosalpingography Hysteroscopy Infant, Newborn Insulin Laparoscopy Males Motility, Cell Ovary Ovulation Pelvis Pharmaceutical Preparations Polycystic Ovary Syndrome Pregnancy Prolactin Sperm Testosterone Thyroid Diseases Uterus Woman
2
Risk Factors for Recurrent Pregnancy Loss
Studies were selected if the prevalence of the abnormal test results for RPL was reported. Only studies which compared women with two pregnancy losses to women with three or more losses were included. Based on current reviews of the literature, the following evidence-based risk-factors for RPL were considered in this review: parental structural chromosomal abnormalities, uterine anomalies, APS, inherited thrombophilia and thyroid disorders. Results of parental chromosomal analysis were considered abnormal if significant rearrangements (e.g. balanced translocations and mosaics) were present. Studies were selected when chromosome analyses were performed with parental peripheral blood lymphocyte cultures. Studies for uterine anomalies were selected if diagnostic testing was performed by hysterosalpingography, hysteroscopy or sonohysterography. Congenital abnormalities (e.g. arcuate uterus, septate uterus, bicornuate uterus and unicornuate uterus) were considered as uterine anomalies.
APS was defined as the presence of thrombosis, pregnancy loss or female morbidity and persistent circulating antiphospholipid antibodies (aPL). aPLs (lupus anticoagulant, IgM anticardiolipin antibodies, IgG anticardiolipin antibodies and beta-2 glycoprotein 1 antibodies) were considered to be present if a test was positive on two occasions >12 weeks apart (Miyakis et al., 2006 (link)).
Inherited thrombophilia was defined in four different sub-categories: Factor V Leiden mutation, prothrombin gene mutation, protein S deficiency and protein C deficiency. Factor V Leiden mutation was considered abnormal if there was a heterozygous or homozygous factor V Leiden G1691A mutation found. Prothrombin gene mutation was defined as heterozygous or homozygous mutations for the G20210A prothrombin (factor II) gene. Functional protein C activity less than 70% and functional protein S activity less than 70% were considered abnormal.
Thyroid disorders were defined as serum levels of thyroid-stimulating hormone (TSH) <0.45 mU/L or TSH >4.5 mU/L with an abnormal free thyroxine level with or without the presence of thyroid peroxidase antibodies.
Studies were excluded when the population examined or the diagnostic methods used were not accurately defined. Only publications in English were considered in our selection.
van Dijk M.M., Kolte A.M., Limpens J., Kirk E., Quenby S., van Wely M, & Goddijn M. (2020). Recurrent pregnancy loss: diagnostic workup after two or three pregnancy losses? A systematic review of the literature and meta-analysis. Human Reproduction Update, 26(3), 356-367.
Publication 2020
Antibodies Antibodies, Anticardiolipin Antiphospholipid Antibodies beta 2-Glycoprotein I Bicornuate Uterus Blood Culture Chromosome Aberrations Chromosomes Congenital Abnormality Diagnosis factor V Leiden Females Gene Rearrangement Genes Heterozygote Homozygote Hysterosalpingography Hysteroscopy Lupus Coagulation Inhibitor Lymphocyte Mutation Parent Pregnancy Protein C Protein C Deficiency Protein S Protein S Deficiency Prothrombin Serum Thrombophilia, hereditary Thrombosis Thyroid Diseases thyroid microsomal antibodies Thyrotropin Thyroxine Translocation, Chromosomal Uterine Anomalies Uterus Uterus, Septate Woman
3
Embryo Assessment: Microscopy vs. aCGH
Following IRB approval, patients undergoing IVF at our programs in Beijing and Los Angeles were offered enrollment in this prospective, single-blind, pilot interventional study to compare embryo assessment by conventional microscopy alone or with array comparative genomic hybridization (aCGH) performed on trophectoderm. Written informed consent was obtained from all study participants and all received pre-treatment counseling in anticipation of possible incorporation of aCGH in their IVF treatment. Patients were eligible for this study if (female) age was <35 yrs, if there was a history of regular ovulation, if etiology of infertility was tubal factor or male factor (or both), and if no prior IVF treatment had been initiated. Additionally, all study subjects were required to have a normal intrauterine contour (confirmed by hysteroscopy), both ovaries intact, basal serum FSH and estradiol on d2-3 at <10 IU/l and <60 pg/ml, respectively. IVF patients whose treatment incorporated donor gametes or frozen/thawed embryos were excluded. A random number table was used to determine patients in vitro laboratory management strategy as either (1) traditional morphology assessment plus aCGH (Group A, n = 55), or (2) conventional morphology assessment only (Group B, n = 48). Patients (but not laboratory or clinical staff) were blinded with regard to their randomization group. The two cohorts were mutually exclusive, and no study patient had embryos assigned to both laboratory groups.
Yang Z., Liu J., Collins G.S., Salem S.A., Liu X., Lyle S.S., Peck A.C., Sills E.S, & Salem R.D. (2012). Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. Molecular Cytogenetics, 5, 24.
Full text: Click here
Publication 2012
Array-Based Comparative Genomic Hybridization Embryo Estradiol Freezing Gametes Hysteroscopy Males Microscopy Ovary Ovulation Patients Serum Sterility, Reproductive Tissue Donors Woman
4
Immediate vs Delayed FET Outcomes
This was a retrospective cohort study conducted at the Department of Reproductive Medicine Center in the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. From April 2014 to December 2017, a total of 4404 patients were enrolled in this study. Inclusion criteria included: 1) women were 20 to 40 years of age, 2) had a normal menstrual cycle (defined as a spontaneous cycle length of ≥21 days and ≤ 35 days), 3) basal FSH<12mIU/ml, 4) the first FET cycle after whole embryo freezing using vitrification method, 5) COS regimens during IVF/ICSI cycle was the gonadotrophin releasing hormone agonist (GnRHa) or GnRH antagonist (GnRHant) protocol. Exclusion criteria included the following: 1) oocyte donation and cycles with preimplantation genetic testing (PGT), 2) patients were diagnosed with polycystic ovary syndrome (PCOS) or ovulation disorder, 3) known uterine anomalies confirmed by 3-dimensional sonography and/or hysteroscopy, including endometrial polyps, septal uterine cavity, submucucosal fibroid, etc.,4) the presence of hydrosalpinx not corrected surgically prior to FET, 5) uncontrolled endocrine and/or immune disorders or other systemic diseases, including hypertension, diabetes, thyroid disease, hyperprolactinemia, antiphospholipid syndrome, systemic lupus erythematosus, etc. Each patient has signed a informed consent on obtaining and analyzing their clinical data prior to the initiation of IVF/ICSI-ET treatment.
The FET cycles were divided in two groups according to the interval between withdrawal bleeding after ovum pick-up (OPU) and the start of the first FET. Immediate FET: women whose endometrial preparation of FET cycle performed within the first menstrual cycle following withdrawal bleeding; and delayed FET: women who had at least one menstrual cycle before initiation of endometrial preparation,and the transferred embryo were cryopreserved for less than 6 months. Furthermore, each group was divided into two subgroups according to COS protocols, and the reproductive and neonatal outcomes were analyzed between the immediate and delayed FET groups following the same COS protocol.
He Y., Zheng H., Du H., Liu J., Li L., Liu H., Cao M, & Chen S. (2020). Delayed frozen embryo transfer failed to improve live birth rate and neonatal outcomes in patients requiring whole embryo freezing. Reproductive Biology and Endocrinology : RB&E, 18, 1.
Full text: Click here
Publication 2020
Antiphospholipid Syndrome Dental Caries Diabetes Mellitus Embryo Endometrial Cycle Endometrium Fibroid Tumor Gonadorelin High Blood Pressures Hyperprolactinemia Hysteroscopy Immune System Diseases Infant, Newborn Lupus Erythematosus, Systemic Menarche Menstrual Cycle Menstruation Oocyte Donation Operative Surgical Procedures Ovulation Ovum Patients Pharmaceutical Preparations Polycystic Ovary Syndrome Polyps Reproduction Sperm Injections, Intracytoplasmic System, Endocrine Thyroid Diseases Treatment Protocols Ultrasonography Uterine Anomalies Uterus, Septate Vitrification Woman
5
Comprehensive Fertility Experiences Questionnaire
We initially conducted a literature review to identify questionnaires that possibly included domains of interest for our research [7 (link), 11 (link)–20 (link)]. We also contacted authors to obtain copies of their instruments, where possible. We used items verbatim from some questionnaires [12 (link), 13 (link)], and adapted items from others (as referenced in Table 1). Based on this review and consultation with experts in the field, we constructed a questionnaire with the domains of interest for our research, called here the fertility experiences questionnaire (FEQ).

Domains, components, details and sources in the fertility experiences questionnaire

DomainsaWritten component (paper or online)Phone interview componentDetails
General health [28 (link)]XExercise, tobacco, caffeinated beverages, alcohol, past medical history, pap smear
Menstrual historyXAge at menarche, frequency and intensity of menses (when not taking hormonal birth control or fertility treatment)
Sexual historyXNumber of lifetime sex partners, history of sexually transmitted infection
Pregnancies and attempts to conceive [23 (link)]Definitions and list of attemptsVerification and detailed questions about attemptsStart month/year for “attempt,” how attempt started and ended, partner for attempt
Desire to conceive during each attempt [29 (link)]XLikert scale for desire for pregnancy and pereceived partner desire for pregnancy at beginning, middle and end of each attempt
Pregnancy outcomes [11 (link)]Dates and types of outcomesVerification and detailsLive birth, miscarriage, ectopic, stillbirth, molar pregnancy, termination, currently pregnant, other, and date ended. For live birth: state where born, birth weight, sex, hospital stay of 7 days or more, breastfeeding.
Fertility-related medical evaluationsbXUltrasound of uterus/ovaries, follicular ultrasound, hysterosalpingogram, hysteroscopy, D&C, blood tests
Fertility-related surgeriesbXC-section, cervical cryotherapy or LEEP, laparoscopy, laparotomy, surgical treatment of endometriosis, surgery on ovaries, tubes, or uterus, other abdominal or pelvic surgery, partner vasectomy reversal, partner other urologic surgery
Fertility-related diagnosesbXUnexplained infertility, endometriosis, PCOS, low progesterone or estrogen, not ovulating, abnormal ovulation, limited cervical mucus, pelvic adhesions, blocked fallopian tubes, uterine fibroids, uterine polyps, luteal phase defect, male factor, other
Fertility treatments recommended by physician or practitioner, and reasons for using or declining treatmentsXDetails about treatments received, and linking timing to attempts to conceive, and whether linked to conceptionFertility-enhancing drugs, artificial insemination, in vitro fertilization with or without intracytoplasmic sperm injection, donor semen or donor eggs, acupuncture, fertility diets, herbal treatments
Self-help measures for trying to conceive (fertility awareness, diet, etc.)Ascertained and linked to attempts to conceive, and whether linked to conceptionTimed intercourse by counting days, basal body temperature, urine ovulation test kits, cervical mucus or fluid; took herbs, fertility vitamins, or supplements; lost weight; adhered to fertility diets; took a daily drug to enhance fertility; took a drug for ovulation; took hormones like progesterone
Adoption experiencesXEver applied for adoption, any adopted children
Stress and social situation [12 (link)]XLikert scale questions about impact of fertility problems and/or treatment on life, relationships with partner, family, friends; level of support from family, partner, friends; negative reactions from family, partner, friends.
Experience of past fertility treatment[12 (link)]XLikert scale questions about perceptions of past treatment: had enough time, shared decision making, feeling listened to, receiving explanations, addressing emotional issues
Demographic informationXMarital status and date, education, race, ethnicity, country of birth, country of parents’ birth, languages spoken, religious preference, occupation, income, whether have written records of fertility experiences, best times to contact by phone
Friends and family with infertilityXNumber of friends or family diagnosed with infertility, friends or family members who have used any of the fertility measures listed previously above
Hypothetical interest in participating in studies of fertility treatmentXWould she have been willing to participate in a study that would involve lifestyle advice, education about fertile days, herbs or acupuncture, medication, artificial insemination, or IVF.
Sources of informationXXDid the participant consult written records to complete the questionnaire?

aCitations indicate other studies from which sections of the questionnaire were taken or adapted

bItems in these sections of the questionnaire were adapted from questions used in research conducted by Mary Croughan, PhD, University of California, San Francisco

Thomas F.S., Stanford J.B., Sanders J.N., Gurtcheff S.E., Gibson M., Porucznik C.A, & Simonsen S.E. (2015). Development and initial validation of a fertility experiences questionnaire. Reproductive Health, 12, 62.
Full text: Click here
Publication 2015
Abdomen Artificial Insemination Awareness Basal Bodies Beverages Birth Weight BLOOD Cervix Mucus Childbirth Coitus Cryotherapy Diet Dietary Supplements Eggs Emotions Endometriosis Estrogens Ethanol Ethnicity Fallopian Tubes Family Member Fertility Fertilization in Vitro Friend Hormonal Contraception Hormones Hydatidiform Mole Hysterosalpingography Hysteroscopy Laparoscopy Laparotomy Luteal Phase Males Menarche Menstruation Neck Operative Surgical Procedures Ovary Ovulation Parent Pelvis Pharmaceutical Preparations Physicians Plant Embryos Polycystic Ovary Syndrome Polyps Pregnancy Progesterone Sexual Partners Sperm Injections, Intracytoplasmic Spontaneous Abortion Sterility, Reproductive Therapy, Acupuncture Tissue Adhesions Tissue Donors Tobacco Products Ultrasonography Urinalysis Uterine Fibroids Uterus Vasovasostomy Vitamins

Most recents protocols related to «Hysteroscopy»

1
Hysteroscopy Anesthesia Optimization Protocol
The study was approved by the Ethics Committee of Weifang People’s Hospital and registered at http://www.chictr.org.cn (Chinese Clinical Trial Registry, ChiCTR2200057803). The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. Informed consent was signed by the patients and their families who participated in the study.
Patients proposed for hysteroscopy day surgery under total intravenous anesthesia, aged 18 to 65 years, American Society of Anesthesiologists (ASA) grade I or II were selected. Exclusion criteria were breastfeeding, a history of chronic pain, a history of sedative and analgesic administration or allergy to any of the study drugs, severe hypertension, and diabetes mellitus. Reject criteria were a procedure time of more than 1 hour, discharged the next day, missing follow-up with the electronic questionnaire pushed 24 hours after the procedure. The included patients were randomized into 3 groups: dexamethasone plus saline group (DC group), dexamethasone plus droperidol group (DD group) and dexamethasone plus propofol group (DP group). The DC group was used as the control group and the remaining 2 groups as the intervention group. Random allocation of included patients by an independent researcher using Excel 2016 (Microsoft) with a 1:1:1 allocation. The participating patients, the outcome assessment fellows, were unaware of the group allocation, only the doctor administering the anesthetic was aware of the grouping of patients and all patients were anesthetized by the same anesthetist.
Patients were routinely fasted and no pre operative medication was administered. After the patient entered the operating room, the intravenous channel was established, and the patient’s ECG, SPO2, NIBP, and BIS were monitored. Patients in each group were given dexamethasone 5 mg for anti-inflammatory and antiemetic prophylaxis before induction, and flurbiprofen axetil 50 mg for preemptive analgesia. Induction of anesthesia: remimazolam 6 mg/kg/hours was continuously infused until sleep, and then mivacurium 0.2 mg/kg and alfentanil 20 ug/kg were slowly injected, after 3 minutes of mask ventilation, the laryngeal mask was placed by the anesthesiologist and mechanical ventilation was performed. Anesthesia maintenance: alfentanil 40 ug/kg/hours and remimazolam 1 mg/kg/hour continuous infusion, stop infusion at the end of the operation. BIS value was maintained between 40 and 60, and 0.1 mg/kg of mivacurium was injected intermittently when necessary. After the start of surgery DC group was given 2ml saline, DD group was given droperidol 1 mg, and DP group was given propofol 20 mg. After awakening and extubation, the patient was taken to the postanesthesia care unit (PACU) and assessed for nausea and vomiting. Patients were discharged after meeting discharge criteria as assessed by the Post-anesthetic Discharge Scoring System (PADSS) criteria. An electronic follow-up questionnaire was pushed 24 hours after the operation. Basic information about the patient’s medical history and surgery was obtained through pre operative anesthesia clinic assessment, intraoperative anesthesia monitoring, in the inpatient electronic medical record, and observation notes in the PACU.
Xiao H., Liu M., Man Y., Wei Y, & Ji F. (2023). Effect of low-dose propofol combined with dexamethasone on the prevention of postoperative nausea and vomiting in gynaecological day surgery under remimazolam-based general anesthesia. Medicine, 102(10), e33249.
Publication 2023
Alfentanil Analgesics Anesthesia Anesthesia, Intravenous Anesthesiologist Anesthetics Anesthetist Anti-Inflammatory Agents Antiemetics Chinese Chronic Pain Dexamethasone Diabetes Mellitus Droperidol Drug Allergy Ethics Committees, Clinical flurbiprofen axetil High Blood Pressures Hysteroscopy Inpatient Laryngeal Masks Management, Pain Mechanical Ventilation Mivacurium Nausea Operative Surgical Procedures Patient Discharge Patients Pharmaceutical Preparations Physicians Propofol remimazolam Saline Solution Saturation of Peripheral Oxygen Sedatives Sleep Surgery, Day Tracheal Extubation
2
Diminished Ovarian Reserve Management: Vitrified Oocyte Accumulation vs. Fresh Oocytes
DOR was made in accordance with the Poseidon (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) classification groups 3 and 4 [28 (link)], defined as the presence of low serum AMH hormone level (< 1.2 ng/ml) or low AFC (< 5) at time of ovarian stimulation initiation. All patients who met the criteria of Poseidon Groups 3 and 4 and had at least one embryo created intended to transfer during the current cycle were included.
Exclusion criteria were coexisting endocrine disorders (diabetes mellitus, untreated hyperprolactinemia, untreated thyroid dysfunction, congenital adrenal hyperplasia, and Cushing’s syndrome), untreated hydrosalpinx, and uterine anomaly confirmed either by hysterosalpingography or hysteroscopy. After applying the exclusion criteria, 440 DOR women who underwent fresh ET were included for final analysis. The study group included 211 patients with vitrified M-II oocyte accumulation for later simultaneous insemination. This group was named “diminished ovarian reserve, accumulation of vitrified oocytes” (DOR-Accu). In this group, we used double stimulation in the same ovarian cycle to maximize the oocyte number retrieved in a short time frame [29 (link), 30 (link)]. After oocyte retrieval, all mature oocytes were vitrified and stored. Then, luteal phase ovarian stimulation following oocyte retrieval was performed based on the number of remainder AFC. The decision about whether to stop oocyte accumulation was based on two factors as follows: (1) the vitrified M-II oocytes’ total number reaches 10–15, which was expected to maximize the LBR [31 (link)–33 (link)], and (2) the patient’s own decision.
The control group included 229 DOR patients who underwent GnRH antagonist protocol, whose fresh mature oocytes were inseminated, and subsequent ET was named “diminished ovarian reserve, fresh oocytes” (DOR-fresh). Surplus embryos in both groups had been vitrified and transferred in their following cycle until surplus embryos were exhausted or the patient got at least one live infant delivery.
Lee K.S., Lin M.H., Hwu Y.M., Yang J.H, & Lee R.K. (2023). The live birth rate of vitrified oocyte accumulation for managing diminished ovarian reserve: a retrospective cohort study. Journal of Ovarian Research, 16, 49.
Full text: Click here
Publication 2023
Cushing Syndrome Diabetes Mellitus Embryo Endocrine System Diseases Gonadorelin Hormones Hyperplasia, Congenital Adrenal Hyperprolactinemia Hysterosalpingography Hysteroscopy Infant Insemination Luteal Phase Obstetric Delivery Oocyte Retrieval Oocytes Ovarian Reserve Ovarian Stimulation Patients Reading Frames Serum Thyroid Gland Uterine Anomalies Woman
3
Comprehensive Management of Cornual Ectopic Pregnancy
All CSP cases were treated by ultrasound-guided vacuum aspiration followed by supplementary curettage. Adjuvant treatment modalities included systemic administration of MTX at a dose of 50 mg/m2 by intramuscular injection (17 (link)), UAE, and hysteroscopy before ultrasound-guided vacuum aspiration. Choices of adjuvant treatment were made according to the advice of the attending physician in discussion with the patients. Informed consent for treatments was acquired from each patient. Patients with type II or type III CSP frequently received systemic MTX before the operation; UAE was recommended for cases with abundant blood flow surrounding the gestation sac, identified by Doppler ultrasound, or when the gestational age was more than 8 weeks. When the remaining uterine myometrium was considered weak or a niche was suspected to be formed, hysteroscopy was used for detailed examination. MTX and UAE were administered within 24–72 h before the operation.
Experienced gynecological surgeons performed ultrasound-guided vacuum aspiration, while the same group of doctors experienced in diagnostic medical sonography performed the scan. Ultrasound was performed throughout the entire operation. First, the gestation sac was located by ultrasound, followed by careful vacuum aspiration. The size of the metal suction tube was determined based on the gestational week. The implanted site of the gestational sac was gently curetted to ensure complete removal of the gestational tissue.
Blood loss was estimated by suction and weighing of swabs. The amount of bleeding during the operation was considered an important indicator of the outcome to measure the effectiveness of each method. The estimated blood loss was compared according to the gestational age at diagnosis and the type of CSP. Intraoperative bleeding greater than 20 ml was considered significant; regular ultrasound-guided vacuum aspiration followed by supplementary curettage only caused 2–5 ml of intraoperative bleeding in our hospital. When there was active bleeding immediately after ultrasound-guided vacuum aspiration operation or the intraoperative blood loss was greater than approximately 50 ml, uterine tamponade strategies such as intrauterine balloon were employed. For this purpose, a Foley catheter was inserted into the uterine cavity under ultrasound guidance at the end of the operation and the balloon was inflated to 5–50 ml in volume until active bleeding ceased.
All patients received routine follow-up care at the clinic approximately 1 month after the operation.
Yang X., Zheng W., Wei X., Ma J., Yan J., Poon L.C, & Yang H. (2023). Management of cesarean scar pregnancy: Importance of gestational age at diagnosis and disease type—A single center’s 5 years of experience involving 223 cases. Frontiers in Surgery, 10, 1055245.
Full text: Click here
Publication 2023
Blood Circulation Catheters Curettage Debility Dental Caries Diagnosis Follow-Up Care Gestational Age Gestational Sac Hysteroscopy Intramuscular Injection Metals Myometrium Patients Pharmaceutical Adjuvants Physicians Pregnancy Radionuclide Imaging Selection for Treatment Suction Drainage Surgeons Surgical Blood Losses Tissues Ultrasonography Ultrasounds, Doppler Uterine Balloon Tamponade Uterus Vacuum Curettage
4
Cesarean Scar Pregnancy: Retrospective Cohort
This was a retrospective cohort study of 223 confirmed cases of CSP out of 253 suspected cases of CSP treated at Peking University First Hospital, Beijing, China, between January 1, 2014, and December 31, 2018. Thirty patients were excluded from the present study for the following reasons: seven patients with type I to II CSP continued pregnancy under careful monitoring and resulted in a live birth. Three patients terminated pregnancy by a cesarean section or induced labor at 12–20 weeks for vaginal bleeding and abdominal pain, with intraoperative bleeding of 300–500 ml. Others underwent laparoscopic operation due to clinical manifestations, including vaginal bleeding, abdominal pain and anemia, lack of myometrium larger than 5 mm × 5 mm, and abundant blood flow under color Doppler, which were considered difficult for hemostasis under hysteroscopy, with intraoperative bleeding of 5–50 ml. This study was approved by the ethics committee of Peking University First Hospital (ID:2016[1266]), and it was a secondary analysis of existing data. Because this is a research hospital, patients are notified that their clinical data might be used for future data analysis in the admission notification. All patients signed informed consent forms for future data analysis at the time of admission to the hospital. Inclusion criteria are as follows: (1) a transvaginal ultrasound was undertaken to confirm the diagnosis of CSP at our hospital before an ultrasound-guided vacuum aspiration procedure; (2) a history of previous cesarean section; and (3) documentation of gestational age at diagnosis of CSP. Exclusion criteria are as follows: (1) spontaneous miscarriage without the need for surgical intervention; (2) missing operative data; (3) reexamination that showed no evidence of CSP; and (4) surgical repair of the cesarean section scar using laparoscopic/transabdominal approaches immediately after the ultrasound-guided vacuum aspiration procedure as part of a single surgery (following consultation with the attending physicians). Data on the highest β-human chorionic gonadotropin (β-hCG) level, administration of systemic methotrexate (MTX), performance of uterine artery embolization (UAE), and hysteroscopy before the ultrasound-guided vacuum aspiration procedure were collected.
Yang X., Zheng W., Wei X., Ma J., Yan J., Poon L.C, & Yang H. (2023). Management of cesarean scar pregnancy: Importance of gestational age at diagnosis and disease type—A single center’s 5 years of experience involving 223 cases. Frontiers in Surgery, 10, 1055245.
Full text: Click here
Publication 2023
Abdominal Pain Anemia Blood Circulation Cesarean Section Cicatrix Diagnosis Ethics Committees, Clinical Gestational Age Hemostasis Human Chorionic Gonadotropin Hysteroscopy Labor, Induced Laparoscopy Methotrexate Myometrium Operative Surgical Procedures Patients Physicians Pregnancy Spontaneous Abortion Surgical Procedures, Laparoscopic Ultrasonography Uterine Artery Embolization Vacuum Curettage
5
Endometrial Evaluation in Abnormal Uterine Bleeding
Data from women presenting with AUB between January 2013 and December 2015 at Women’s Hospital, Zhejiang University School of Medicine were evaluated retrospectively. Only patients whose preoperative TVUS examination and histopathological findings were fully documented were included in the study. The exclusion criteria included already known malignancies, existing pregnancy, and endometrial sampling within the past 3 months. Complete data sets with information on age, body mass index [BMI=weight (kg)/height2 (m2)], menstrual history, medical history (diabetes and hypertension), and family history (endometrium, breast, and colon carcinoma) were available for 1369 patients. Obesity was defined as BMI ≥25 kg/m2. Patients enrolled in this study underwent either hysteroscopy or D&C after ultrasound examination. Histopathological evaluation of all endometrial samples was performed by gynecologic pathologists. Patients undergoing endometrial evaluation between January 2020 and January 2021 were assigned to the validation group. This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Women’s Hospital, Zhejiang University School of Medicine (approval number: IRB-20210233-R). No additional patient informed consent was required, given the retrospective nature of this study.
Ruan H., Chen S., Li J., Ma L., Luo J., Huang Y., Ying Q, & Zhou J. (2023). Development and Validation of a Nomogram Prediction Model for Endometrial Malignancy in Patients with Abnormal Uterine Bleeding. Yonsei Medical Journal, 64(3), 197-203.
Publication 2023
Breast Cancer of Colon Diabetes Mellitus Endometrium Ethics Committees, Clinical High Blood Pressures Hysteroscopy Index, Body Mass Malignant Neoplasms Menstruation Obesity Pathologists Patients Pregnancy Ultrasonography Woman

Top products related to «Hysteroscopy»

1
Spss software by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium, China, Italy, India, Israel, France, Spain, Denmark, Canada, Hong Kong, Poland, Australia
SPSS is a software package used for statistical analysis. It provides a graphical user interface for data manipulation, statistical analysis, and visualization. SPSS offers a wide range of statistical techniques, including regression analysis, factor analysis, and time series analysis.
2
Dydrogesterone by Abbott
Sourced in United States, Netherlands
Dydrogesterone is a synthetic progestogen compound that is used in laboratory research and testing. It is a chemical substance that acts similarly to the natural hormone progesterone, which is involved in the regulation of the menstrual cycle and pregnancy.
3
Hysterovideoscope hyf type 5 by Olympus
Sourced in Japan
The Hysterovideoscope HYF type V is a medical device designed for diagnostic and surgical procedures. It is used for the visual examination and recording of the uterus and surrounding structures. The device provides a high-quality video image, allowing for detailed observation and documentation.
4
Collagenase type 1 by Merck Group
Sourced in United States, Germany, United Kingdom, China, Macao, Sao Tome and Principe, France, Japan, Switzerland, Israel, Spain, Australia, Italy, Canada
Collagenase type I is an enzyme used in laboratory settings to break down collagen, a structural protein found in various tissues. It is commonly used in cell isolation and tissue dissociation procedures.
5
Rnasafer reagent by Magen Biotechnology Co
Sourced in China
RNAsafer reagent is a laboratory product designed to preserve and stabilize RNA samples. It prevents RNA degradation during sample collection, storage, and handling.
6
Eswab tube by Copan
Sourced in Italy
The ESwab tubes are a collection and transport system designed for the collection and transport of specimens. The tubes contain a liquid Amies-based transport medium that helps maintain the viability of microorganisms during transport to the laboratory.
7
Progynova by Bayer
Sourced in Germany, France, China, Belgium
Progynova is a laboratory equipment product manufactured by Bayer. It is a device used for the analysis and measurement of progesterone levels in biological samples. The core function of Progynova is to provide accurate and reliable results for progesterone testing in research and clinical settings.
8
Rnalater by Qiagen
Sourced in Germany, United States, Spain, United Kingdom, Netherlands, Canada, Japan, Switzerland, France, Australia, Belgium, Italy, Sweden
RNAlater is a stabilization solution designed to rapidly permeate tissues and cells to stabilize and protect cellular RNA immediately after sample collection. It allows samples to be stored at ambient temperature for extended periods without degradation of RNA.
9
Endomat by Storz
Sourced in Germany
The Endomat is a laboratory equipment product designed for performing endoscopic procedures. It serves as a suction and irrigation unit, providing a controlled flow of fluids during endoscopic examinations and interventions. The Endomat is intended to assist medical professionals in their clinical applications.
10
Cetrorelix by Merck Group
Sourced in Germany, France, Switzerland, Belgium, United Kingdom, Italy, Australia, United States
Cetrorelix is a synthetic peptide that functions as a gonadotropin-releasing hormone (GnRH) antagonist. It acts by blocking the GnRH receptor, thereby inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.

More about "Hysteroscopy"

Hysteroscopy is a minimally invasive medical procedure used to examine the interior of the uterus.
It involves the insertion of a thin, lighted instrument called a hysteroscope through the cervix to visualize the uterine cavity.
This procedure is often used to identify and treat various uterine conditions, such as abnormal bleeding, fibroids, polyps, and adhesions.
Hysteroscopy can be performed in an outpatient setting and is generally well-tolerated by patients.
Accurate and reproducible hysteroscopy findings are crucial for effective clinical management.
PubCompare.ai offers an AI-driven protocol comparison tool to help researchers locate, evaluate, and optimize hysteroscopy procedures based on the latest published literature, preprints, and patents.
The Hysterovideoscope HYF type V is a specialized hysteroscope that can be used during the procedure.
Collagenase type I is an enzyme that may be used to help break down tissue during hysteroscopy.
RNAsafer reagent and ESwab tubes can be used to collect and preserve samples for analysis.
Dydrogesterone is a synthetic progestogen that may be used in conjunction with hysteroscopy to treat certain uterine conditions.
Progynova is a brand name for estradiol valerate, a hormone that can also be used in conjunction with hysteroscopy.
SPSS software can be utilized to analyze and interpret the data collected during hysteroscopy procedures.
RNAlater is a reagent that can be used to preserve RNA samples for molecular analysis.
Endomat is a specialized device used to control the flow of fluid during hysteroscopy, and Cetrorelix is a medication that may be used to suppress ovulation during the procedure.
By leveraging the latest technologies and research insights, PubCompare.ai helps researchers optimize hysteroscopy protocols and achieve reproducible, accurate results.
Experience the future of hysteroscopy research today with PubCompare.ai.